Antenatal corticosteroids to reduce preterm deaths in low-income settings
In their Comment 1 on the use of antenatal corticosteroids to reduce preterm infant deaths, Kishwar Azad and Anthony Costello advise "extreme caution" before scale-up in low-income settings. They emphasise maternal sepsis as a concern but cite only one trial in which dexamethasone resulted in a significant increase in fever that required antibiotic treatment compared with controls (relative risk [RR] 2·05, 95% CI 1·14-3·69; 118 women).
1,2 We suggest that this fi nding alone does not refl ect a balanced assessment of the paucity of evidence available.
2
In a systematic review of antenatal corticosteroid treatment to accelerate fetal lung maturation, only four of 21 randomised controlled trials report on puerperal sepsis outcomes for dexamethasone versus no antenatal corticosteroids and these show moderate heterogeneity (I² 38%) (RR 1·74, 95% CI 1·04-2·89; 536 women).
2 Only two trials were in low-income to middle-income countries and had very diff erent results: the Dexiprom trial from South Africa (0·57, 0·17-1·89; 204 women) and one trial from Jordon (4·19, 0·94-18·68; 139 women). Incidence of maternal postnatal fever did not differ in two trials, the US Collaborative trial (0·93, 0·56-1·53; 682 women) and the Dexiprom trial in South Africa (1·00, CI 0·36-2·75; 204 women). Most reassuringly, no signifi cant diff erence was reported in the incidence of chorioamnionitis in four trials of dexamethasone (1·35, 0·89-2·05; 575 women) or postnatal fever in two trials of dexamethasone (0·94, 0·60-1·47; 886 women).
2 No trials of dexamethasone reported on maternal intrapartum fever when antibiotics were given.
Trials of betamethasone versus dexamethasone in accelerating fetal lung maturation have not reported on maternal infectious outcomes. 3 We are currently undertaking a largescale trial to compare the efficacy of intramuscular dexamethasone versus betamethasone in reducing childhood neurosensory disability, with maternal infection as a secondary outcome. 4 Currently, no published data suggest a major risk of maternal infection with the use of antenatal corticosteroids and none are available to allow confi dent assertion that dexamethasone increases the risk. According to present recommendations, the major safety concern surrounding the use of antenatal corticosteroids is repeat doses.
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